Chronic Hepatitis B Market Expansion Continues, with Forecast Valuation of $4.59 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Chronic Hepatitis B Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market associated with chronic hepatitis b has experienced consistent expansion lately; projections indicate a rise from $3.77 billion in 2024 to $3.93 billion the subsequent year, reflecting a compound annual growth rate (CAGR) of 4.2%. This upward trajectory throughout the historical timeframe stems from several factors, including progress in treatments utilizing antiviral agents, expanding promotional efforts by governmental bodies and non-governmental organizations, enhancements in methods for disease detection, the increasing incidence of HIV infections, and greater public consciousness about the condition.

Chronic Hepatitis B Market Size Forecast: What's the Projected Valuation by 2029?
Projections indicate that the market for chronic hepatitis B will experience consistent expansion over the coming years, reaching a value of $4.59 billion by 2029, driven by an anticipated compound annual growth rate (CAGR) of 4.0%; this upward trajectory is underpinned by factors such as the penetration into nascent regions, increased allocation of resources and supportive governmental legislation, advancements in identifying and testing for the condition, escalating healthcare spending, a rise in strategic alliances and cooperative agreements, the societal trend of an increasing median age, and widespread public education initiatives, while key market developments moving forward will involve a pivot towards treatments offering complete cures, further development in developing economies, upgrades in diagnostic capabilities and early detection methods, the formation of new alliances, and an intensified emphasis on care models tailored to individual patient needs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

What Are the Drivers Transforming the Chronic Hepatitis B Market?
Anticipated expansion in the sheer
volume of chronic hepatitis B cases is set to fuel the advancement of the market dedicated to this condition. Hepatitis B represents a liver ailment caused by the hepatitis B virus (HBV), which fortunately has a preventative vaccine available. A confluence of elements contributes to the escalating incidence of hepatitis B, particularly within nations categorized as low- and middle-income, where insufficient vaccination uptake results in elevated transmission risks because substantial segments of the population lack immunity. Surging numbers of hepatitis B infections naturally precipitate a greater need for both detection methods and therapeutic interventions. To illustrate this, data released in June 2024 by the Centers for Disease Control and Prevention (CDC), an agency of the United States government, suggested that achieving 90% global vaccination coverage against hepatitis B and ensuring 80% access to treatment could avert 26 million new infections and 9 million fatalities linked to hepatitis B between 2022 and 2050. Moreover, the year 2022 saw 1.2 million newly diagnosed cases of HBV infection; consequently, the widespread nature of hepatitis B infection serves as the primary impetus for growth within the chronic hepatitis B virus market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp

What Long-Term Trends Will Define the Future of the Chronic Hepatitis B Market?
Leading firms within the chronic hepatitis B landscape are concentrating their efforts on progressing technology, notably through the introduction of new antiviral treatments; these innovative pharmaceutical agents function by obstructing viral reproduction and employing sophisticated delivery mechanisms, explicitly aiming at difficult-to-treat infections, with several molecules currently undergoing rigorous assessment for both safety and therapeutic impact, one such example being bepirovirsen directed against chronic hepatitis B. Reflecting this development, GSK plc, the multinational healthcare giant headquartered in the UK with expertise spanning research, production, and sales across numerous health sectors, secured the U.S. Food and Drug Administration's Fast Track status in February 2024 for bepirovirsen, an experimental antisense oligonucleotide therapeutic intended for chronic hepatitis B (CHB) management; this therapeutic agent is engineered specifically to locate and eliminate the messenger RNA of the hepatitis B virus (HBV), consequently offering the potential for the body's natural defenses to reassert command over the persistent infection, building upon encouraging data from its Phase IIb evaluations, notably the B-Clear and B-Sure investigations, which confirmed its capability in lowering levels of hepatitis B surface antigen (HBsAg) and sustaining viral suppression over time.

Which Segments in the Chronic Hepatitis B Market Offer the Most Profit Potential?
The chronic hepatitis bmarket covered in this report is segmented -

1) By Drug Class: Antivirals; Immune Modulators
2) By Gender: Male; Female
3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers

Subsegments:
1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir); Interferons (Pegylated Interferon)
2) By Immune Modulators: Immune Checkpoint Inhibitors; Therapeutic Vaccines (HBV Vaccines Under Development)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=17112&type=smp

Which Firms Dominate the Chronic Hepatitis B Market by Market Share and Revenue in 2025?
Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

Which Regions Offer the Highest Growth Potential in the Chronic Hepatitis B Market?
North America was the largest region in the chronic hepatitis B market in 2024. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17112

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.